2013-11-14T14:28:08-06:00 2012-12-31 521392008 GELMAN ROSENBERG & FREEDMAN 4550 MONTGOMERY AVE SUITE 650N BETHESDA MD 208142930 990 2012-01-01 943384500 PATH DRUG SOLUTIONS INST 2062853500 2201 WESTLAKE AVENUE NO 200 SEATTLE WA 98121 OLIVIA POLIUS 2062853500 2013-11-14 1 3019519090 2012 2016-02-25 16:41:14Z X OLIVIA POLIUS 2201 WESTLAKE AVENUE NO 200 SEATTLE WA 98121 24403194 0 X WWW.ONEWORLDHEALTH.ORG X 2000 CA SEE PART III, LINE 1. 7 4 25 0 0 0 15708021 2365799 0 0 78945 72342 0 14983 15786966 2453124 1895400 5066914 0 0 4015023 1852778 0 0 0 7766314 4732178 13676737 11651870 2110229 -9198746 24285254 28999523 1581867 2883967 22703387 26115556 X PATH DRUG SOLUTIONS (PDS) WORKS TO IDENTIFY AND DEVELOP SAFE AND EFFECTIVE NEW MEDICINES FOR DISEASES THAT DISPROPORTIONATELY AFFECT PEOPLE IN DEVELOPING COUNTRIES, AND ENSURE THAT THEY ARE AVAILABLE AND ACCESSIBLE WHERE THEY ARE NEEDED MOST. 0 0 4394184 2829253 EMERGING AND EPIDEMIC DISEASES: ALTHOUGH MANY POOR COUNTRIES NEED NEW, MORE EFFECTIVE, AND LOWER-COST MEDICINES TO MEET HEALTH CHALLENGES (INCLUDING MALARIA, DIARRHEA, AND NEGLECTED AND TROPICAL DISEASES), RESEARCH AND DEVELOPMENT FOR THESE DRUGS MAY NOT BE A PRIORITY FOR COMMERCIAL PHARMACEUTICAL GROUPS. PDS OVERCOMES THIS BARRIER BY CREATING CROSS-SECTOR COLLABORATIONS, OPENING DOORS FOR THE SHARING AND DONATION OF INTELLECTUAL PROPERTY, AND HARNESSING THE SCIENTIFIC AND MANUFACTURING CAPACITY OF BOTH DEVELOPED AND DEVELOPING COUNTRIES. WE ASSEMBLE EXPERIENCED AND DEDICATED TEAMS, IDENTIFY PROMISING DRUG CANDIDATES, TRANSLATE THEM INTO SAFE, EFFECTIVE, AND AFFORDABLE MEDICINES, AND COLLABORATE WITH COMPANIES TO MANUFACTURE AND DISTRIBUTE NEWLY APPROVED THERAPIES TO THOSE WHO NEED THEM MOST.IN 2012, THE TEAM ACHIEVED REMARKABLE GAINS, DEVELOPING TRANSFORMATIVE NEW MEDICINES AND RESEARCH WHILE MODELLING AND ADVANCING BEST PRACTICE IN CROSS-SECTOR COLLABORATION.FOR EXAMPLE, THE HIGH COST AND VOLATILE SUPPLY OF ARTEMISININ, THE KEY INGREDIENT IN TOP MALARIA TREATMENTS, CAN PUT THESE LIFESAVING MEDICINES OUT OF REACH FOR PEOPLE WHO ARE MOST AT RISK. WE WORKED WITH PARTNERS TO DEVELOP A SEMISYNTHETIC VERSION OF ARTEMISININ TO SUPPLEMENT FLUCTUATING BOTANICAL SUPPLIES AND, AFTER SUCCESSFULLY COMPLETING PROCESS VALIDATION, PRODUCED SEVERAL TONS OF MATERIALS FOR TESTING BY POTENTIAL CUSTOMERS. PRODUCTION IS SET FOR 40 TONS IN 2013, AND WILL EXPAND SIGNIFICANTLY BY 2014, PROVIDING A MORE DEPENDABLE SUPPLY OF ARTEMISININ, AND ULTIMATELY, LIFESAVING ANTIMALARIAL DRUGS.THE NEW DRUG, AND THE INNOVATIVE SCIENTIFIC PROCESSES THAT ALLOW PRODUCTION AT AN INDUSTRIAL SCALE, ARE BOTH SET TO ACHIEVE GLOBAL IMPACT. IN ADDITION, THE EFFORT DEMONSTRATED SUCCESSFUL COLLABORATION BETWEEN INDUSTRY, SCIENTIFIC, NONPROFIT, AND ACADEMIC PARTNERS. PATH'S TEAM SYNCHRONIZED DIVERGENT GOALS, PROFESSIONAL NORMS, AND INTELLECTUAL PROPERTY CONSIDERATIONS TO BRING THE PRODUCT TO COMMERCIAL PRODUCTION, FURTHERING PATHS EXPERIENCE AND REPUTATION AS A LEADER IN CROSS-SECTOR COLLABORATION FOR PUBLIC HEALTH.IN ADDITION, PDS ADVANCED A NEW TREATMENT OPTION FOR VISCERAL LEISHMANIASIS, A NEGLECTED INFECTIOUS DISEASE ENDEMIC IN 79 COUNTRIES THAT IS TRANSMITTED THROUGH THE BITE OF SAND FLIES, CAUSING SWELLING OF KEY ORGANS, ANEMIA, AND DEATH IF LEFT UNTREATED. WE ADVANCED A NEW ANTIBIOTIC CALLED THE PAROMOMYCIN INTRAMUSCULAR INJECTION (PMIM), DEVELOPED TO TREAT THE DISEASE. IN 2012, IT WAS REGISTERED BY THE GOVERNMENT OF NEPAL, AND WE COMPLETED A PHASE 3(B) CLINICAL TRIAL IN BANGLADESH, SUPPORTING EFFORTS TO REGISTER PMIM THERE AND CONTRIBUTING TO A NATIONAL ELIMINATION STRATEGY. 5969238 2138740 MATERNAL AND CHILD HEALTH: WE COMPLETED TWO PHASE 1 CLINICAL STUDIES IN THE UNITED STATES FOR A NEW DRUG CANDIDATE TO TREAT ACUTE SECRETORY DIARRHEA. THIS WORK IS PART OF PATH'S WIDE-REACHING EFFORTS TO COMBAT DIARRHEA, ONE OF THE LEADING CAUSES OF DEATH AMONG CHILDREN UNDER FIVE. THE STUDIES SHOWED THAT THE TREATMENT WAS SAFE, WELL TOLERATED, AND HAD NO SERIOUS ADVERSE EVENTS. BASED ON THESE OUTCOMES, WE WILL CONTINUE TO ADVANCE THIS PROMISING DRUG CANDIDATE THROUGH FURTHER CLINICAL TRIALS IN BANGLADESH IN 2013. 17492 9583 HEALTH TECHNOLOGIES: WE PERFORMED WORK, WHICH WILL CONTINUE INTO NEXT YEAR, ON DEVELOPING A NEW FORMULATION OF ORAL REHYDRATION SOLUTION THAT ADDRESSES SYMPTOMS CAUSED BY DIARRHEA. 137108 89338 OTHER PROGRAM SERVICES 137108 89338 10518022 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 1 0 1 1 1 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 21 0 1 25 1 0 1 IN 0 0 0 0 0 0 0 0 X 7 4 0 0 1 0 0 0 0 1 1 0 0 1 1 1 1 1 1 0 0 0 CA WA X X OLIVIA POLIUS CHIEF FINANCIAL OFFICER 2062853500 2201 WESTLAKE AVENUE SUTIE 200 SEATTLE WA 98121 CHRISTOPHER J ELIAS 1.00 39.00 X X 0 223504 12905 STEVEN DAVIS 1.00 39.00 X X 0 215600 19353 ERIC G WALKER 1.00 39.00 X X 0 252022 37003 DANIEL LASTER 1.00 39.00 X X 0 215725 34457 JACQUELINE SHERRIS 2.00 38.00 X 0 0 0 TOM BREWER 2.00 1.00 X 0 0 0 KEN DUNCAN 2.00 0.00 X 0 0 0 JORGE FLORES 2.00 0.00 X 0 0 0 TUE NGUYEN 40.00 0.00 X 182097 55171 17832 EUGENIO DE HOSTOS 40.00 0.00 X 93349 70814 21738 HEATHER KELLY 40.00 0.00 X 89462 56102 12479 JOHN DONNELLY 40.00 0.00 X 0 160572 0 MAHMOOD KUTUBUDDIN 40.00 0.00 X 0 147228 4552 SHAYE STAMATIS 40.00 0.00 X 98561 64505 11296 RAJ SHANKAR GHOSH 40.00 0.00 X 89256 34315 15207 552725 1495558 186822 1 0 1 0 FOLEY & LARDNER 555 SOUTH FLOWER ST 3500 LOS ANGELES CA 90071 LEGAL 207289 HALO PROJECT 41 E 11TH ST 11TH FL NEW YORK NY 10003 COMM./PR/MEDIA SVCS. 134661 CAROL A HILL 123 ROSS STREET SANTA CRUZ CA 95060 CLINICAL OPERATIONS 122062 PHILIPPE DESJEUX 899 RUE JEAN DE GINGINS DIVONNE FR CONSULTING 117361 CYNTHIA A RASK 2186 A VALLEJO STREET SAN FRANCISCO CA 94123 CONSULTING 101850 5 1231793 1134006 2365799 72412 72412 21950000 21950070 -70 -70 -70 OTHER REIMBURSEMENTS 900099 14983 14983 14983 2453124 0 0 87325 3606346 3606346 1460568 1460568 301775 274421 27354 1240856 914354 326502 49250 49250 154829 154829 106068 106068 220897 194157 26740 9350 7850 1500 974744 839875 134869 1349 1349 93196 50280 42916 36173 22791 13382 191995 4937 187058 394485 392973 1512 138066 137545 521 22781 22781 41857 33358 8499 SUBCONTRACTS 2325598 2325598 LAB SUPPLIES 152882 152882 EQUIPMENT R&M / PROC. 91048 77272 13776 BUSINESS DUES/FEES 13534 10743 2791 24223 10723 13500 11651870 10518022 1133848 0 700953 277683 2437357 21622683 644591 6799174 62254 372743 138279 147007 49201 203056 97806 19926554 1644 24285254 28999523 1581867 2883967 1581867 2883967 X 587263 620484 22116124 25495072 22703387 26115556 24285254 28999523 X -9198746 -35948 12646863 X 0 1 X 1 0 X X X 0 0 0 PROGRAM FOR APPROPRIATE TECHNOLOGY IN HEALTH 911157127 7 1 11651870 1 11651870 RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 49899 16832 33067 97108 32369 64739 97806 1 EAST ASIA AND THE PACIFIC 0 0 PROGRAM SERVICES MATERNAL AND CHILD HEALTH 353964 EUROPE 0 0 PROGRAM SERVICES EMERGING AND EPIDEMIC DISEASES 120631 EUROPE 0 0 PROGRAM SERVICES MATERNAL AND CHILD HEALTH 149971 EUROPE 0 0 MANAGEMENT & GENERAL 1145 EUROPE 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION 1300000 NORTH AMERICA 0 0 PROGRAM SERVICES MATERNAL AND CHILD HEALTH 84624 SOUTH ASIA 2 6 PROGRAM SERVICES MATERNAL AND CHILD HEALTH 116415 SOUTH ASIA 0 0 PROGRAM SERVICES EMERGING AND EPIDEMIC DISEASES 944991 SOUTH ASIA 0 0 MANAGEMENT & GENERAL 147942 SOUTH ASIA 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION 160568 2 6 0 0 2 6 3071741 308510 3380251 EUROPE EMERGING AND EPIDEMIC DISEASES 1300000 CHECK/WIRE SOUTH ASIA EMERGING AND EPIDEMIC DISEASES 146344 CHECK/WIRE SOUTH ASIA EMERGING AND EPIDEMIC DISEASES 14224 CHECK/WIRE 1 2 1 0 0 0 0 0 PROCEDURE FOR MONITORING GRANTS OUTSIDE THE U.S.: SCHEDULE F, PART I, LINE 2: SUBRECIPIENTS ARE REQUIRED TO SUBMIT PROGRESS REPORTS, WHICH ARE REVIEWED BY RESPONSIBLE PATH PROGRAM MANAGERS AND PROGRAM ADMINISTRATORS TO ENSURE THAT PROGRAM GOALS ARE ATTAINED IN ACCORDANCE WITH AGREEMENT REQUIREMENTS. THE RESPONSIBLE PROGRAM MANAGERS AND PROGRAM ADMINISTRATORS CONTACT SUBRECIPIENTS WITH QUESTIONS AND FOLLOW UP ON ANY CONCERNS. IN SOME CASES, SUBAWARD TERMS MAY REQUIRE SPECIFIED DELIVERABLES IN ADDITION TO, OR IN LIEU OF, TECHNICAL AND FINANCIAL REPORTS. IN ADDITION, DISCRETIONARY ON-SITE VISITS ARE CONDUCTED TO EVALUATE BOTH COMPLIANCE WITH THE SCIENTIFIC OBJECTIVES OF THE PROJECT AND THE APPROPRIATENESS OF THE SUBRECIPIENT'S ADMINISTRATIVE SYSTEMS AND PROCESSES. 1 ST LOUIS UNIVERSITY 3545 LINDELL BLVD ST LOUIS MO 63103 430654872 501(C)(3) 245123 MATERNAL & CHILD HEALTH MPI RESEARCH 54943 N MAIN STREET MATTAWAN MI 49071 383400587 501(C)(3) 52300 MATERNAL & CHILD HEALTH PROGRAM FOR APPROPRIATE TECHNONOGY IN HEALTH 2201 WESTLAKE AVE SUITE 200 SEATTLE WA 98121 911157127 501(C)(3) 3308923 GENERAL SUPPORT 3 0 PROCEDURE FOR MONITORING GRANTS IN THE U.S.: PART I, LINE 2: SCHEDULE I, PART I, LINE 2: SUBRECIPIENTS ARE REQUIRED TO SUBMIT PROGRESS REPORTS, WHICH ARE REVIEWED BY RESPONSIBLE PROGRAM MANAGERS AND PROGRAM ADMINISTRATORS TO ENSURE THAT PROGRAM GOALS ARE ATTAINED IN ACCORDANCE WITH AGREEMENT REQUIREMENTS. THE RESPONSIBLE PROGRAM MANAGERS AND PROGRAM ADMINISTRATORS CONTACT SUBRECIPIENTS WITH QUESTIONS AND FOLLOW UP ON ANY CONCERNS. IN SOME CASES, SUBAWARD TERMS MAY REQUIRE SPECIFIED DELIVERABLES IN ADDITION TO, OR IN LIEU OF, TECHNICAL AND FINANCIAL REPORTS. IN ADDITION, DISCRETIONARY ON-SITE VISITS ARE CONDUCTED TO EVALUATE BOTH COMPLIANCE WITH THE SCIENTIFIC OBJECTIVES OF THE PROJECT AND THE APPROPRIATENESS OF THE SUBRECIPIENT'S ADMINISTRATIVE SYSTEMS AND PROCESSES. 0 0 0 0 0 0 0 0 0 CHRISTOPHER J ELIAS 0 100133 0 123321 0 50 0 12016 0 889 0 236409 0 0 STEVEN DAVIS 0 205500 0 10000 0 100 0 12241 0 7112 0 234953 0 0 ERIC G WALKER 0 234809 0 10000 0 7213 0 26368 0 10635 0 289025 0 0 DANIEL LASTER 0 205697 0 10000 0 28 0 23873 0 10584 0 250182 0 0 TUE NGUYEN 137902 55171 44195 0 0 0 1184 5192 9119 2337 192400 62700 0 0 EUGENIO DE HOSTOS 67043 70814 26306 0 0 0 331 913 15694 4800 109374 76527 0 0 HEATHER KELLY 82274 56102 7188 0 0 0 625 3719 6470 1665 96557 61486 0 0 JOHN DONNELLY 0 160572 0 0 0 0 0 0 0 0 0 160572 0 0 MAHMOOD KUTUBUDDIN 0 147228 0 0 0 0 0 1044 0 3508 0 151780 0 0 SHAYE STAMATIS 98561 64505 0 0 0 0 1758 5243 3776 519 104095 70267 0 0 PART I, LINE 3 PDS RELIES ON A RELATED ORGANIZATION, PATH, TO DETERMINE COMPENSATION. PATH USES THE FOLLOWING METHODS TO ESTABLISH COMPENSATION: - COMPENSATION COMMITTEE - INDEPENDENT COMPENSATION CONSULTANT - COMPENSATION SURVEY OR STUDY - APPROVAL BY THE BOARD OR COMPENSATION COMMITTEE FORM 990, PART VI, SECTION A, LINE 4 ON JANUARY 1, 2012, PATH DRUG SOLUTIONS (PDS), PREVIOUSLY KNOWN AS INSTITUTE FOR ONEWORLD HEALTH, BECAME AN ORGANIZATION ORGANIZED AND OPERATED EXCLUSIVELY FOR THE BENEFIT OF OR TO CARRY OUT THE PURPOSES OF PROGRAM FOR APPROPRIATE TECHNOLOGY IN HEALTH (PATH), A WASHINGTON NONPROFIT PUBLICLY SUPPORTED ORGANIZATION. PDS, WHICH ALSO HAS OFFICES IN NEW DELHI AND PATNA, INDIA, CURRENTLY WORKS ON DRUG DEVELOPMENT PROJECTS FOR DISEASES THAT INCLUDE DIARRHEAL DISEASE, MALARIA, AND VISCERAL LEISHMANIASIS. BY BECOMING A PATH AFFILIATE, PDS WILL BE ABLE TO SCALE AND ACCELERATE ITS SUCCESSFUL DRUG DEVELOPMENT EFFORTS. PDS WILL REMAIN A NONPROFIT ORGANIZATION OPERATING OUT OF ITS SOUTH SAN FRANCISCO HEADQUARTERS. FORM 990, PART VI, SECTION B, LINE 11 THE FORM 990 WAS PREPARED BY AN OUTSIDE ACCOUNTING FIRM USING INFORMATION PROVIDED BY PATH ACCOUNTING SERVICES STAFF. PATH SENIOR MANAGEMENT REVIEWED THE DRAFT FORM. A COPY OF THE DRAFT WAS SENT TO THE BOARD OF DIRECTORS FOR COMMENT. AFTER THE COMMENT PERIOD, THE PRESIDENT AND CEO SIGNED THE RETURN. FORM 990, PART VI, SECTION B, LINE 12C PATH BOARD MEMBERS, PDS MANAGEMENT, AND ALL STAFF ABOVE A DESIGNATED LEVEL IN THE ORGANIZATION MUST COMPLETE A CONFLICT OF INTEREST DISCLOSURE FORM EACH YEAR. ALL FORMS ARE REVIEWED AND KEPT ON FILE. A CONFLICT MANAGEMENT PLAN IS DEVELOPED FOR ANY EMPLOYEE WITH A SIGNIFICANT ACTUAL OR PERCEIVED CONFLICT OF INTEREST. FORM 990, PART VI, SECTION C, LINE 19 PDS MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON REQUEST. CHANGES IN NET ASSETS OR FUND BALANCES: FORM 990, PART XI, LINE 9: FAIR VALUE DIFFERENCE (GAIN) OF RE-VALUED ONEWORLD 12,646,863. HEALTH NET ASSETS UPON ACQUISITION ON 1/1/12 PROGRAM FOR APPROPRIATE TECHNOLOGY IN HEALTH 2201 WESTLAKE AVE SUITE 200 SEATTLE WA 98121 911157127 GLOBAL HEALTH WA 501(C)(3) LINE 7 N/A 0 PATH VACCINE SOLUTIONS 2201 WESTLAKE AVE SUITE 200 SEATTLE WA 98121 830431851 ADVANCE DEVELOPMENT OF VACCINES TO IMPROVE THE HEALTH OF CHILDREN WA 501(C)(3) LINE 7 PATH 1 ORGANIZATION FOR APPROPRIATE TECHNOLOGY IN HEALTH 25 BUILDING B0 SHOTA RUSTAVELI STR KYIV UP REDUCE THE BURDEN IN UKRAINE UP N/A N/A PATH 1 FOUNDATION FOR APPROPRIATE TECHNOLOGIES IN HEALTH - SWITZERLAND 207 ROUTE DE FERNEY 1218 LE GRAND-S GENEVA SZ EDUCATIONAL AND SCIENTIFIC PROMOTION OF HEALTH SZ N/A N/A PATH 1 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0